Role of molecular biomarker human papilloma virus (HPV) E6 oncoprotein in cervical cancer screening
Authors:
- 1 September 2020
- journal article
- research article
- Published by Elsevier in Gynecologic Oncology
- Vol. 158 (3) , 590-596
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trialThe Lancet Oncology, 2012
- Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA studyThe Lancet Oncology, 2011
- Age-Specific Evaluation of Primary Human Papillomavirus Screening vs Conventional Cytology in a Randomized SettingJNCI: Journal of the National Cancer Institute, 2009
- Performance of Human Papillomavirus DNA and mRNA Testing Strategies for Women with and without Cervical NeoplasiaJournal of Clinical Microbiology, 2009
- HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trialThe Lancet Oncology, 2009
- HPV Screening for Cervical Cancer in Rural IndiaNew England Journal of Medicine, 2009
- Efficacy of HPV DNA Testing With Cytology Triage and/or Repeat HPV DNA Testing in Primary Cervical Cancer ScreeningJNCI: Journal of the National Cancer Institute, 2009
- Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trialThe Lancet, 2007
- Overview of the European and North American studies on HPV testing in primary cervical cancer screeningInternational Journal of Cancer, 2006
- Reproducibility of HPV DNA Testing by Hybrid Capture 2 in a Screening SettingAmerican Journal of Clinical Pathology, 2005